Zai Lab Highlights Early Trial Data for ZL-1503 in Atopic Dermatitis Treatment
Zai Lab shared initial Phase 1 findings for its atopic dermatitis drug candidate, ZL-1503, highlighting safety and target engagement in healthy volunteers.
🌍World BusinessPhoto: Seeking Alpha
Key points
- Zai Lab presented Phase 1 data for ZL-1503 at a medical meeting.
- The compound targets both IL-13 and IL-31 pathways for atopic dermatitis.
- Patient multiple ascending dose data is expected in the first half of next year.
Zai Lab Limited executives discussed early-stage clinical findings for ZL-1503, an internally developed bispecific antibody designed to address atopic dermatitis. Speaking during an investor conference call on November 13, 2026, company leadership detailed the results from the initial Phase 1 evaluation of the treatment.
Rafael Amado, the company's President and Head of Global Research and Development, reported that the treatment successfully met all pre-defined objectives regarding safety, half-life duration, and target engagement during tests involving healthy participants. The compound is engineered to inhibit both the IL-13 cytokine ligand and the IL-31 receptor alpha.
Following the healthy volunteer evaluation, the clinical trial is advancing to assess multiple ascending doses in patients suffering from atopic dermatitis. Leadership indicated that these forthcoming patient-focused findings are anticipated during the first half of the following year.
What to watch next: Investors should look for the multiple ascending dose patient results scheduled for release in the first half of next year.
Source Seeking Alpha — seekingalpha.com/article/4967815-zai-lab-limited-zlab-discusses-zlminus… ↗
Read next
📈MarketsMemory Chip Makers Surge as AI Infrastructure Demand Outstrips Supply Through 2030
Surging demand for memory chips driven by artificial intelligence infrastructure has pushed sales up dramatically for leading hardware providers.
🏢CompaniesNvidia Faces Scrutiny as Up to 20% of Asian Revenue Tied to Complex China Supply Chains
Nvidia co-founder Jensen Huang stepped down as CEO following an investigation, while reports highlight that roughly 20% of the tech giant's fiscal 2026 compute revenue ma…
📈MarketsBitcoin Million-Dollar Target Unrealistic by 2030, Industry Executive Warns
Dragonfly Capital managing partner Haseeb Qureshi states that Bitcoin hitting $1 million by 2030 is unlikely, projecting a more modest cycle peak instead.
📈MarketsWise Shares Rally 8.5% Following Strong First-Half Results and $141 Billion in Payments
Wise Group saw its stock jump 8.55% to $11.87 after reporting a 23% rise in net revenue to $1.453 billion, driven by robust cross-border transaction volumes.
💼InvestingCentral Puerto Reports 70% Jump in Adjusted EBITDA as Fuel Strategy Pays Off
Argentine energy producer Central Puerto posted a 70% year-over-year increase in third-quarter adjusted EBITDA to $185.3 million, driven by direct fuel procurement and st…
💼InvestingTurning 62 in 2027? Three Social Security Rules to Keep in Mind
Workers reaching age 62 in 2027 face critical Social Security timing rules that impact their retirement income, monthly check delivery schedules, and earnings limits.